Global Head and Neck Cancer Therapeutics Market to reach USD 2.01 billion by 2027.Global Head and Neck Cancer Therapeutics Market is valued approximately USD 1.07 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 9.4% over the forecast period 2021-2027. Head and neck cancers are caused by malignant tumors that grow around the throat, nose, sinuses, salivary glands and mouth. Increase in occurrence of head & neck cancer across the world, rising awareness and demand for therapy to cure head and neck cancer, and growth in research activities are driving the Head and Neck Cancer Therapeutics market. The major risk factors for cancers of the head and neck are alcohol and tobacco. All tobacco products, including cigarettes and smokeless tobacco are linked to head and neck cancer. Drinking alcohol, such as beer, wine, or liquor, also raises the risk of getting cancers of the mouth, throat, and voice box. According to WHO's Global Health Observatory, the total per capita alcohol consumption in India is expected to increase to 7.9 liters in 2025 from current 6.6% liters 2020. Similarly, the figure for United States is 10.3L from 10.1 L, 11.5L to 11.8L for UK and 8.1L from 7.5 for China in period 2020-2025. The increase in the alcohol consumption indicates the increase in consequent diseases, including cancers. Therapies to the head and neck may cause redness or skin irritation, tooth decay, speech problems and hearing loss. This issue may act as a restraint for its growth. However, increasing efforts from government and private entities in research and development of cancer therapies acts as an opportunity for Head and Neck Cancer Therapeutics Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Head and Neck Cancer Therapeutics Market. Due to higher investment in research activities in cancer treatment as well as higher per capita income, North America has emerged as a significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit the highest growth rate for the forecast period 2021-2027 owing to the growing population with affinity for alcoholic beverages and tobacco. Rising disposable income will also boost growth in this region.

Major market player included in this report are:
AstraZeneca Plc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Fresenius Medical Care AG & Co. KGaA
Merck & Co., Inc.
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Chemotherapy
Immunotherapy
Targeted Therapy

By Sales Channel:
Hospital pharmacy
Online providers
Drug stores & retail pharmacies

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Head and Neck Cancer Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors